Clarion clinics, page-55

First 55 Last

Share
Profile

Follow
Breakingsystem

453 Posts.

228

07/06/24

13:24

Post #: 74215417
Share

Originally posted by Flectional: ↑

your take is interesting in a number of areas - and not accurate dc

the fact that the recipient can identify they have taken a sugar pill ( in this particular case) rather than the drug under trial does not indicate an adverse outcome for the trail endpoints - rather the reverse is true and substantially so - to undergo the psychotherapy set after taking the trial medication and finding no differentiation or change in the patient condition would indicate immediately to the patient they have been dosed with an ineffective medication ....in this case a sugar pill.
This is exactly what you would want if you were conducting the trial - why? this is the opposite of the placebo effect verifying the test cohort outcomes comparative to the outcomes of those on the real medication.

the FDA committee indicated major failures with the trial design that Lykos conducted - blinding protocols being a major factor - as a result blinding must be administered, scrutinized and meticulously aligned with the psychotherapy set for quality data to be in evidence - this was not the case with this Lykos trial - as the FDA stated they in fact ignored procedural recommendations by the advisory contributing to the trial failure.

Clarion outcomes to date (Dr Paul and PSI -GAD) have had no such issues
PsiGAD-1 is a randomised triple-blind active-placebo-controlled Phase 2 trial. The primary objective of the study is to determine whether a 7-week program of psilocybin-assisted psychotherapy for GAD is superior to active placebo-assisted psychotherapy in decreasing symptoms of GAD, as measured by the change in the Hamilton Anxiety Rating Scale (HAM-A) from baseline to week 11. Safety and tolerability were assessed, as well as other secondary objectives of efficacy and quality of life.

Expand

Don’t Freak Out. It Isn’t the End of the Line for Psychedelic Medicines

https://www.barrons.com/articles/mmda-ecstacy-psychedelic-medicines-fda-7130bf1c

IHL Price at posting: 4.1¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

LU7

Lithium Universe targets silver boom with breakthrough solar recycling tech

LIS

Li-S Energy the latest microcap to pivot to US defence market

LDX

Lumos Diagnostics surges 140% on major US contract deal

ASX Market Close: Why are we red today? Because US CPI's at 3%

First 55 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Clarion clinics, page-55

Top Stories

Listen: HotCopper Wire Podcast 018 – Potatoes, TACOs, and the $120M helicopter heist

Lithium Universe targets silver boom with breakthrough solar recycling tech

Li-S Energy the latest microcap to pivot to US defence market

Lumos Diagnostics surges 140% on major US contract deal

ASX Market Close: Why are we red today? Because US CPI's at 3%

Featured News